AstraZeneca and its global biologics research and development arm, MedImmune, announced that the European Medicines Agency has granted access to its PRIME, or PRIority MEdicines, scheme for MEDI8897, an extended half-life respiratory syncytial virus F monoclonal antibody being developed for the prevention of lower respiratory tract infection caused by RSV. Mene Pangalos, Executive Vice-President, R&D BioPharmaceuticals, said: “We are excited to receive PRIME eligibility for MEDI8897, our next-generation monoclonal antibody targeting respiratory syncytial virus in infants. We will work closely with the European Medicines Agency to optimise our development plan and help us bring MEDI8897 to patients as quickly as possible.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.